Frederick BE - Search Results

1

How well do physicians recognize melanoma and other problem lesions?

Cassileth BR, Clark WH Jr, Lusk EJ, Frederick BE, Thompson CJ, Walsh WP. Cassileth BR, et al. Among authors: frederick be. J Am Acad Dermatol. 1986 Apr;14(4):555-60. doi: 10.1016/s0190-9622(86)70068-6. J Am Acad Dermatol. 1986. PMID: 3958271 Free article.

2

Patient and physician delay in melanoma diagnosis.

Cassileth BR, Temoshok L, Frederick BE, Walsh WP, Hurwitz S, Guerry D, Clark WH Jr, DiClemente RJ, Sweet DM, Blois MS, et al. Cassileth BR, et al. Among authors: frederick be. J Am Acad Dermatol. 1988 Mar;18(3):591-8. doi: 10.1016/s0190-9622(88)70081-x. J Am Acad Dermatol. 1988. PMID: 3351022

3

"Catalyst" symptoms in malignant melanoma.

Cassileth BR, Lusk EJ, Guerry D 4th, Clark WH Jr, Matozzo I, Frederick BE. Cassileth BR, et al. Among authors: frederick be. J Gen Intern Med. 1987 Jan-Feb;2(1):1-4. doi: 10.1007/BF02596240. J Gen Intern Med. 1987. PMID: 3806266

4

Reactivity of the human antiendotoxin immunoglobulin M monoclonal antibody HA-1A with lipopolysaccharides from rough and smooth gram-negative organisms.

Mascelli MA, Frederick B, Ely T, Neblock DS, Shealy DJ, Pak KY, Daddona PE. Mascelli MA, et al. Infect Immun. 1993 May;61(5):1756-63. doi: 10.1128/iai.61.5.1756-1763.1993. Infect Immun. 1993. PMID: 8478065 Free PMC article.

5

Abciximab pharmacodynamic model with neural networks used to integrate sources of patient variability.

Urquidi-Macdonald M, Mager DE, Mascelli MA, Frederick B, Freedman J, Fitzgerald DJ, Kleiman NS, Abernethy DR. Urquidi-Macdonald M, et al. Clin Pharmacol Ther. 2004 Jan;75(1):60-9. doi: 10.1016/j.clpt.2003.09.008. Clin Pharmacol Ther. 2004. PMID: 14749692

6

Human monoclonal antibody HA-1A binds to endotoxin via an epitope in the lipid A domain of lipopolysaccharide.

Bogard WC Jr, Siegel SA, Leone AO, Damiano E, Shealy DJ, Ely TM, Frederick B, Mascelli MA, Siegel RC, Machielse B, et al. Bogard WC Jr, et al. J Immunol. 1993 May 15;150(10):4438-49. J Immunol. 1993. PMID: 7683319

7

Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization.

Lincoff AM, Kereiakes DJ, Mascelli MA, Deckelbaum LI, Barnathan ES, Patel KK, Frederick B, Nakada MT, Topol EJ. Lincoff AM, et al. Circulation. 2001 Jul 10;104(2):163-7. doi: 10.1161/01.cir.104.2.163. Circulation. 2001. PMID: 11447080 Clinical Trial.

8

Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions.

Kleiman NS, Grazeiadei N, Maresh K, Taylor RJ, Frederick B, Lance ET, Effron MB, Jordan RE, Mascelli MA. Kleiman NS, et al. Am Heart J. 2000 Sep;140(3):492-501. doi: 10.1067/mhj.2000.109220. Am Heart J. 2000. PMID: 10966553 Clinical Trial.

9

Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects.

Abernethy DR, Pezzullo J, Mascelli MA, Frederick B, Kleiman NS, Freedman J. Abernethy DR, et al. Clin Pharmacol Ther. 2002 Mar;71(3):186-95. doi: 10.1067/mcp.2002.121775. Clin Pharmacol Ther. 2002. PMID: 11907493

10

Pharmacodynamic profile of short-term readministration of abciximab in healthy subjects.

Freedman J, Mascelli MA, Pezzullo JC, Barnathan ES, Frederick B, Jordan RE, Abernethy DR. Freedman J, et al. Am Heart J. 2002 Jan;143(1):87-94. doi: 10.1067/mhj.2002.119769. Am Heart J. 2002. PMID: 11773917

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

23 results

Search Page

Filters